How A Tough 2022 Could Reshape Biotech

Instigators of Change

From massive supply chain issues to wary investors, 2022 is turning out to be a tough year for biotech. But it's also a sector that's reshaping our lives, as we saw during the pandemic. So what are the most exciting opportunities in biotech right now? And where are the pitfalls? Cellino co-founder Nabiha Saklayen and Khosla Ventures partner Alex Morgan talk about making it through a downturn, machine learning, women in medicine, and the impact of outsiders.